Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1983 Jun;40(3):1075-82.
doi: 10.1128/iai.40.3.1075-1082.1983.

Lack of antibodies to human heart tissue in sera of rhesus monkeys immunized with Streptococcus mutans antigens and comparative study with rabbit antisera

Comparative Study

Lack of antibodies to human heart tissue in sera of rhesus monkeys immunized with Streptococcus mutans antigens and comparative study with rabbit antisera

L A Bergmeier et al. Infect Immun. 1983 Jun.

Abstract

Immunization of rabbits and rhesus monkeys with Streptococcus mutans whole cells, cell walls, and defined streptococcal antigens (SAs) SA I/II, SA I, and SA II resulted in high antibody titers to SA I/II (10(-4) to 10(-6)) when tested by the solid-phase radioimmunoassay. Cross-reactive antibodies to heart homogenates (HH) were not elicited in rhesus monkeys. A few rabbits immunized with cell wall or SA II preparation in Freund complete adjuvant followed by the incomplete adjuvant yielded low antibody titers (up to 10(-2)) to the HH. The specificity of the putative heart cross-reactive antibodies was tested by immunoadsorption with related and unrelated antigens. Whereas antibody to SA I/II showed specific adsorption with SA I/II but not with HH, immunoglobulin G, or the unrelated antigens, antibody to HH seemed to have been adsorbed with all of the related and unrelated antigens. There was no evidence for the development of heart cross-reactive antibodies on immunization of rhesus monkeys or rabbits with SA I/II and aluminium hydroxide or Freund incomplete adjuvant, administered by the subcutaneous or intramuscular route in doses of up to 13 mg of the immunogen.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Infect Immun. 1982 Aug;37(2):656-61 - PubMed
    1. Arch Oral Biol. 1978;23(1):7-15 - PubMed
    1. Nature. 1981 Aug 20;292(5825):770-2 - PubMed
    1. Infect Immun. 1980 Sep;29(3):999-1006 - PubMed
    1. Clin Exp Immunol. 1981 Feb;43(2):417-24 - PubMed

Publication types